Vol. 6 Issue 3 Part A

Background: Cripto-1 is over expressed in tissues and closely correlated with the invasion and proliferation of Hepatocellular carcinoma (HCC) cells. The aim of this work is to measure the serum concentrations of Cripto-1 and its relation to the clinical aggressiveness of HCC in hepatocellular carcinoma (HBV) and hepatitis C virus (HCV) infected individuals.

Methods: This work was performed on 60 individuals with clinical criteria of newly diagnosed HCC, hepatitis related liver cirrhosis and HBV or HCV diagnosed by PCR. Participnts were split into equal five groups: Group I: HCC on top of HBV related cirrhosis. Group II: HCC on top of HCV-related cirrhosis. Group III: HBV with hepatic-cirrhosis and no HCC. Group IV: HCV with hepatic-cirrhosis and no HCC. Group V: healthy subjects as control group.

Results: A statistically substantial rise was exited in the mean values of cripto-1 of HCC and cirrhotic patient groups contrasted to the control group and HCC with HBV HCC with HBV (P=0.001), and there was also significant increase in HCC patients group values and cihrotic HBV patients compared to cirrhotic patient’s groups (P=0.001). In HCC and cirrhotic patients groups a significant positive association was existed among cripto-1 and each of Alpha-fetoprotein (AFP), serum glutamic-pyruvic transaminase (SGPT), serum glutamic-oxaloacetic transaminase (SGOT), and prothrombin time (PT).

Conclusions: Serum levels of cripto-1 is greater in HCC on top of HBV patients than HCC on top of HCV patients. Serum levels of cripto-1 is greater in cihrotic HBV individuals than cihrotic HCV patients. Cripto-1 can be used as aguide in early diagnosis of HCC.